Devonian Health Group Overview
- Founded
-
2015
- Status
-
Public
- Employees
-
7
- Stock Symbol
-
GSD
- Investments
-
2
- Share Price
-
$0.20
- (As of Friday Closing)
Devonian Health Group General Information
Description
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It is intended to develop prescription botanical drugs which could be from plant materials, algae, macroscopic fungi, and combinations thereof. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provide a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. The products of the group include botanical pharmaceuticals, Thykamine; and derma-cosmeceutical product, Purgenesis.
Contact Information
- 360 Rue Des Entrepreneurs
- Montmagny, Quebec G5V 4T1
- Canada
Devonian Health Group Timeline
Devonian Health Group Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.20 | $0.13 | $0.11 - $0.47 | $20.7M | 136M | 8.94K | -$0.03 |
Devonian Health Group Financials Summary
|
In Thousands, USD |
TTM 31-Jan-2023 | FY 2022 31-Jul-2022 | FY 2021 31-Jul-2021 | FY 2020 31-Jul-2020 |
|---|---|---|---|---|
| EV | 35,016 | 49,813 | 39,538 | 13,205 |
| Revenue | 1,683 | 1,815 | 1,156 | 1,592 |
| EBITDA | (1,951) | (1,328) | (1,230) | (1,909) |
| Net Income | (2,845) | (2,715) | (2,624) | (3,249) |
| Total Assets | 14,737 | 16,653 | 11,707 | 12,445 |
| Total Debt | 2,753 | 3,301 | 4,227 | 3,492 |
Devonian Health Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Devonian Health Group Patents
Devonian Health Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3534924-A4 | Composition for the prevention and/or treatment of cardiovascular diseases | Inactive | 04-Nov-2016 | 000000000 | |
| EP-3534924-A1 | Composition for the prevention and/or treatment of cardiovascular diseases | Inactive | 04-Nov-2016 | 000000000 | |
| US-11033592-B2 | Composition for the prevention and/or treatment of cardiovascular diseases | Active | 04-Nov-2016 | 000000000 | 0 |
| US-20190314433-A1 | Composition for the prevention and/or treatment of cardiovascular diseases | Active | 04-Nov-2016 | 000000000 | 0 |
| CA-3039681-A1 | Composition comprising thylakoid extract for use in the prevention and/or treatment of cardiovascular diseases | Pending | 04-Nov-2016 | A61P9/00 |
Devonian Health Group Executive Team (4)
Devonian Health Group Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 000000 00.0 | Devonian Health Group | Chief Scientific Officer & Board Member | 000 0000 |
| 000000 000000000 | Devonian Health Group | President, Chief Executive Officer & Board Member | 000 0000 |
Devonian Health Group Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Devonian Health Group Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Devonian Health Group Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 000000 | 01-Feb-2018 | 0000000000 | 00.000 | Other Healthcare Services | 00000 000 |
| Orletto Capital | 15-May-2017 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) | 00000 000 |